Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Inspyr TherapeuticsCapstone TherapeuticsAeolus PharmaceuticalsAnthera PharmaceuticalsAchaogen
SymbolOTCMKTS:NSPXOTCMKTS:CAPSOTCMKTS:AOLSOTCMKTS:ANTHOTCMKTS:AKAOQ
Price Information
Current Price$0.01$36.01$0.01$0.07$0.03
52 Week RangeN/AN/AN/AN/AN/A
MarketRank™
Overall Score0.50.80.80.50.6
Analysis Score0.00.00.00.00.0
Community Score2.43.02.12.53.2
Dividend Score0.00.00.00.00.0
Ownership Score0.00.81.70.00.0
Earnings & Valuation Score0.00.00.00.00.0
Analyst Ratings
Consensus RecommendationN/AN/AN/AN/AN/A
Consensus Price TargetN/AN/AN/AN/AN/A
% Upside from Price TargetN/AN/AN/AN/AN/A
Trade Information
Market Cap$1.97 million$1.95 million$958,000.00$970,000.00$1.30 million
Beta-16.55176.152.382.19-0.84
Average Volume18,078,461304673,777199,797245,074
Sales & Book Value
Annual RevenueN/A$2 millionN/AN/A$8.73 million
Price / SalesN/A0.97N/AN/A0.15
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value($14.05) per shareN/AN/AN/AN/A
Price / BookN/A∞N/AN/A∞
Profitability
Net Income$-930,000.00$-380,000.00N/AN/A$-186,510,000.00
EPSN/AN/AN/AN/AN/A
Trailing P/E Ratio0.000.000.000.000.00
Forward P/E Ratio∞∞∞∞∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/AN/AN/A
Return on Equity (ROE)N/AN/AN/AN/AN/A
Return on Assets (ROA)-298.11%N/AN/AN/AN/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current RatioN/AN/AN/AN/AN/A
Quick RatioN/AN/AN/AN/AN/A
Ownership Information
Institutional Ownership PercentageN/A2.55%N/AN/A0.03%
Insider Ownership Percentage0.02%42.80%66.60%2.08%7.80%
Miscellaneous
Employees1N/A42142
Shares Outstanding150.00 million54,000152.09 million13.85 million48.21 million
Next Earnings DateN/AN/AN/AN/AN/A
OptionableNot OptionableNot OptionableNot OptionableOptionableOptionable
SourceHeadline
News for Achaogen IncNews for Achaogen Inc
markets.businessinsider.com - December 30 at 8:01 AM
Achaogen: Jetzt wird’s richtig interessantAchaogen: Jetzt wird’s richtig interessant
aktiencheck.de - August 21 at 3:40 PM
Achaogen Inc - Ordinary Shares (AKAOQ)Achaogen Inc - Ordinary Shares (AKAOQ)
nasdaq.com - August 17 at 7:42 AM
Achaogen Inc.Achaogen Inc.
www.marketwatch.com - June 10 at 11:32 PM
AKAOQ Achaogen Inc - Ordinary SharesAKAOQ Achaogen Inc - Ordinary Shares
www.nasdaq.com - April 22 at 8:37 AM
The Finance 202: Risk of Iranian conflict rattles investors. But a serious economic hit looks unlikely.The Finance 202: Risk of Iranian conflict rattles investors. But a serious economic hit looks unlikely.
www.washingtonpost.com - January 6 at 4:00 PM
Achaogen Taps New Buyer for Antibacterial Drug RightsAchaogen Taps New Buyer for Antibacterial Drug Rights
www.wsj.com - October 23 at 6:18 PM
2019 Pyelonephritis Drug Market | Industry Analysis, Size, Share, Strategies and Forecast Till 20242019 Pyelonephritis Drug Market | Industry Analysis, Size, Share, Strategies and Forecast Till 2024
www.marketwatch.com - August 9 at 3:27 PM
Achaogen to Sell Drug Rights, Lab Equipment for $16 MillionAchaogen to Sell Drug Rights, Lab Equipment for $16 Million
www.wsj.com - June 8 at 6:16 AM
Once picked as a $500M win­ner, bank­rupt Achao­gen auc­tions off its an­tibi­ot­ic for a frac­tion of thatOnce picked as a $500M win­ner, bank­rupt Achao­gen auc­tions off its an­tibi­ot­ic for a frac­tion of that
endpts.com - June 7 at 3:17 PM
DateCompanyBrokerageAction
(Data available from 4/17/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.